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Abstract 
Objective:  This study sought to determine if DNA integrity was compromised by ionising 
radiation from paediatric cardiac catheterisations and if dose optimisation techniques allowed 
DNA integrity to be maintained.   
Materials and Methods:  Children were imaged using either: (i) an anti-scatter grid (current 
departmental protocol), (ii) no anti-scatter grid or, (iii) no anti-scatter grid and a 15 cm air-gap 
between the child and the X-ray detector.  Dose area product and image quality were assessed, 
lifetime attributable cancer risk estimates were calculated and DNA double-strand breakages 
quantified using the γH2AX assay.   
Results: Consent was obtained from 70 parents/guardians/children.  Image quality was 
sufficient for each procedure performed.  Removal of the anti-scatter grid resulted in dose 
reductions of 20% (no anti-scatter grid) and 30% (15 cm air-gap), DNA double-strand break 
reductions of 30% (no anti-scatter grid) and 20% (15 cm air-gap) and a reduction of radiation-
induced cancer mortality risk of up to 45%. 
Conclusion: Radiation doses received during paediatric cardiac catheterisation procedures 
resulted in a significant increase in DNA damage while maintaining acceptable image quality 
and diagnostic efficacy.  It is feasible to remove the anti-scatter grid resulting in a reduction in 
DNA damage to the patient.  The γH2AX assay may be used for assessment of dose 
optimisation strategies in children. 
 
Introduction 
The number of paediatric cardiac catheterisation procedures has continued to increase over the 
last decade[1] due to their value in diagnosing and in particular, treating congenital heart 
disease.  Unfortunately paediatric cardiac catheterisation contribute a significant radiation 
burden to children who are 2 - 10 times more sensitive to radiation-induced cancer compared 
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to adults[2-3].  The largest dosimetry study for paediatric cardiac catheterisation in the United 
Kingdom, consisted of >10,000 procedures and demonstrated that almost 50% of children had 
received radiation doses comparable to having >500 chest radiographs[4].  The lifetime risk of 
developing any cancer for children in receipt of numerous medical imaging examinations for 
congenital heart disease has been reported to be as high as 6.5%[5].  Newer flat panel detectors 
are thought to be more dose efficient because they are more efficient at converting X-ray 
photon energy into a corresponding electrical signal[6].  Determining the optimal method of 
imaging using flat panel detectors technology is necessary to minimise radiation dose.  
Simultaneously, it is important to maintain appropriate image quality in accordance with “as 
low as reasonably achievable” principle[7], given that there are no official imaging guidelines 
in this area.  This has led to inconsistent imaging protocols in clinical practice[8].  The successful 
reduction in radiation dose for children is a priority according to the “Image Gently” campaign 
and the World Health Organisation[9]. 
 
The anti-scatter grid is used to absorb scattered radiation, which degrades image quality.  
Employing an anti-scatter grid is common practice in paediatric cardiac catheterisation, 
however some imaging centres remove the anti-scatter grid for children <10 kg[5,10-11] because 
smaller patients are associated with the production of less scatter radiation. Evidence based on 
experiments and simulations on polymethyl methacrylate phantoms that have also shown dose 
reductions up to 50%[10,12-13].  Recently one publication stated that they have begun removing 
the anti-scatter grid in children up to 20 kg but did not state if the anti-scatter needed to be 
reinserted for any of their examinations[14].  Another possible method of scatter removal is to 
remove the anti-scatter grid and employ an air-gap between the patient and the X-ray detector.  
A 15 cm air-gap has been successfully implemented on 122 adult patients undergoing cardiac 
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catheterisations with reported dose reductions of 23 - 39%[15].  The air-gap method has also 
been successfully employed in children <20 kg for cardiac biopsies[16].   
To determine if radiation dose optimisation is achievable measurements of radiation dose and 
image quality are required.  Additionally the lifetime attributable risk (LAR) of cancer 
mortality from radiation exposure can also be obtained.  At present the linear no-threshold 
model is accepted by the International Commission on Radiological Protection (ICRP)[17] and 
assumes that a linear risk is associated with medical radiation doses, typically <100 mSv.  
Biomarkers of radiation exposure may also be used to assess the cellular effects of radiation 
exposure and have been encouraged by the United Nations Scientific Committee on the Effects 
of Atomic Radiation[18].  In particular the highly sensitive γH2AX assay has enabled the 
immunofluorescence of radiation-induced DNA double-strand breaks following ex vivo 
ionising radiation in isolated blood lymphocytes[19-23].  One of the earliest responses is the 
phosphorylation of the histone H2AX at serine 139[24]. The rapid accumulation of γH2AX-foci 
surrounding a double-strand breakage damage site enables a 1:1 assessment of the number of 
double-strand breakages[25].  Recently, authors have used the γH2AX assay to detect double-
strand breakages in children following computed tomography[26-27] and paediatric cardiac 
catheterisation[28]. However, no study has been published which investigates if DNA integrity 
may be maintained by optimising radiation dose during these types of clinical procedure. 
 
This will be the first study to employ the γH2AX assay a biomarker of radiation dose reduction 
during cardiac catheterisation procedures.  The purpose of our study was to conduct a trial in 
paediatric cardiac catheterisation implementing either: (i) an anti-scatter grid (current 
departmental protocol), (ii) no anti-scatter grid or, (iii) no anti-scatter grid and the introduction 
of a 15 cm air-gap.  These imaging methods were assessed for effects upon radiation dose, 
image quality, LAR of cancer mortality and DNA integrity using the γH2AX assay.  
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Materials and methods 
Study population 
The study complied with the Declaration of Helsinki[29].  Upon local governance and ethical 
approval (Ref: 13020CH-AS, Ref: 13/NI/0204), written informed consent was obtained from 
70 consecutive participants aged 0 - 16 years (or their guardians/parents) undergoing paediatric 
cardiac catheterisation in a UK paediatric cardiology centre from 1st April 2014 to 31st March 
2015.  Participants were randomly assigned using a sealed envelope to 1 of the 3 imaging 
methods.   Inclusion criteria were; written informed consent and aged ≤ 16 years. Parental 
consent was obtained from the parent/guardian of the child and if possible, the child provided 
assent. Exclusion criteria were; those unwilling or unable to provide consent, withdrawal from 
participation and emergency referrals. A second set of exclusion criteria for blood sample 
collection was as follows: known cancer, history of radiotherapy or chemotherapy, current viral 
infections, white blood cell disorders e.g. Lymphocytopenia, exposure to toxins, history of 
antioxidant supplementation and physical exercise two hours prior to participation. 
 
Imaging  
Imaging was performed using a Philips Allura Xper bi-plane flat panel detector cardiovascular 
system (Philips healthcare, Amsterdam, Netherlands) that employed an automatic exposure 
control.  Participants were imaged using the “paediatric” setting using 15 pulses per second for 
fluoroscopy and 30 acquisitions per second for CINE acquisition.  The X-ray system employed 
tube energies in the range of 60 - 100 kVp (anti-scatter grid mean 71± s.d. 3.4, No anti-scatter 
grid mean 68± s.d. 4.2, 15 cm air-gap mean 67± s.d. 4).  Pre-set additional filtration of 0.1 mm 
aluminum 0.4 mm copper for fluoroscopy and 0.1 mm aluminum, 0.1 mm copper during CINE 
acquisition was used.  No magnification was required and standard collimation was employed 
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throughout. Clinicians were made aware of the randomly implemented imaging method (anti-
scatter grid, no anti-scatter grid or 15 cm air-gap) and had the option of reverting to the standard 
protocol if necessary by reinserting the anti-scatter grid. In order to remove the grid a safety 
catch is depressed and the grid is easily removed from the equipment or re-inserted if required, 
as illustrated in Figure 1.    
 
Image quality assessment  
The clinician performing the procedure continuously assessed image quality during each 
procedure ensuring that diagnostic efficacy was maintained.  To score image quality without 
potential bias, and permit time to assess on image quality, retrospective blinded scoring was 
performed by two paediatric cardiologists using the Digital Imaging and Communications in 
Medicine images from random procedures.  The researcher ensured that images were available 
from participants who received the highest and lowest radiation dose in the form of dose area 
product for each imaging method from 0 - 20 kg, 20 - 40 kg and >40 kg weight categories.  
Due to insufficient study numbers only 1 participant was assessed for the >40 kg for the no 
anti-scatter grid method.  A 5-point Likert style scoring scale was used to assess image quality 
as used previously related clinical assessments including cardiac catheterisation and neonatal 
chest imaging[15,30].  The image characteristics assessed were based upon normal clinical 
considerations as follows: demonstration of the area of interest, image contrast, image 
sharpness, visualisation of devices/catheters/balloons and overall quality.  These were scored 
as follows: 2 Fully confident criterion is fulfilled, 1 Somewhat confident criterion is fulfilled, 
0 Uncertain whether criterion is fulfilled, -1 Somewhat confident criterion is not fulfilled, -2 
Fully confident that criterion is not fulfilled. 
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Dosimetry  
The dose area product, tube current, tube potential, field of view, focus to image distance, 
number of CINE acquisitions, fluoroscopy time and imaging angles were recorded in order to 
estimate the effective dose. Effective dose is defined by the ICRP. It is the tissue-weighted sum 
of the equivalent doses in all specified tissues and organs of the human body and represents the 
stochastic health risk to the whole body, which is the probability of cancer induction and 
genetic effects, of low levels of ionising radiation. Effective dose and organ dose were 
determined by the Monte Carlo software PCXMC version 2.0 (STUK, Helsinki, Finland).  For 
all exposures made to each child the following were added to the PCXMC program: (i) 
examination data, included corresponding phantom age, height, mass, focus-image distance, 
image and field width by height, phantom exit-image distance, focus-image distance, focus-
skin distance and beam angulation, (ii) photon simulation, included tube potential, X-ray tube 
anode angle and filtration, (iii) input radiation dose for CINE and fluoroscopy (fluoro) entered 
in the form of DAP in mGy∙cm2.  This program applied the tissue weighting factors 
recommended in the ICRP publication 103, 2007[31]. A crude estimation of peak skin dose was 
also made by dividing the dose area product by the field of view for the fluoroscopy and CINE 
acquisitions and adding together the skin dose for all overlapping regions of skin. 
 
Blood dose estimation    
The organ doses calculated for each participant were used to estimate the dose to the blood. 
This was performed by applying the dose to each organ and the weighted fraction of total blood 
volume present in the organ at any given time according to values presented in the ICRP 
publication 89[32].   
 
Blood sample collection  
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Blood samples (1 ml) were collected through the secured vascular access sheath.  One sample 
for each participant was collected prior to imaging to determine baseline numbers of γH2AX-
foci and a second sample taken immediately following the procedure.  Samples were 
immediately stored in a cool box at 4ºC to prevent double-strand break repair reported to occur 
after 30 minutes[24].  
 
 
 
Lymphocyte separation  
Blood samples were added to 1 ml phosphate-buffered solution and carefully layered using a 
pipette onto lymphocyte separation medium Histopaque 1077 (Sigma-Aldrich, Dorset, United 
Kingdom).  Centrifugation was performed at 2,000 rpm for 30 minutes at 21ºC and stopped 
without the use of a brake mechanism.  The lymphocyte layer was aspirated with a pipette, 
placed in 5 mls of phosphate-buffered solution and centrifuged at 1,070 rpm for 5 minutes. The 
resulting lymphocyte cell pellet was washed with phosphate-buffered solution and spotted onto 
superfrost plus slides (Menzel-Glaser, Thermo Fisher Inc, Braunschweig, Germany) and left 
to dry for 30 minutes.  Cells were then fixed with 2% formaldehyde for 10 minutes. 
 
Immunofluorescence and microscopy     
Fixed cells were permeabilised using 0.5% Triton-X100 phosphate-buffered solution for 10 
minutes and blocked in 5% horse serum and 0.1% Triton-X100 phosphate-buffered solution 
for 30 minutes.  Cells were incubated with 1:1000 mouse anti-H2AX phosphorylated 
monoclonal antiphospho-histone H2AX (ser 139) clone (Millipore, Herfortshire) in the dark 
for one hour at room temperature followed by Alexa Fluor 488 goat anti-mouse IgG, IgA and 
IgM (H&L) (Life technologies, Paisley, United Kingdom) in the dark for one hour at room 
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temperature.  Slides were washed with phosphate-buffered solution between each stage and 
then mounted with vectashield hardset DAPI (Vector laboratories, Peterborough, United 
Kingdom).  The numbers of γH2AX-foci were counted using an Olympus BX3 epiflurescence 
microscope with x63 objective.  Due to the dispersal of irradiated lymphocytes in the blood 
circulation 300 lymphocyte cells were scored for each sample. 
 
 
Ex vivo irradiation 
An ex vivo radiation dose response calibration was performed using 7 ml whole blood obtained 
from the antecubital vein of a healthy volunteer.  This blood sample was pipetted into 7 x 1 ml 
eppendorf tubes, which were irradiated to one of the following radiation doses respectively: 0 
mGy, 2.5 mGy, 5 mGy, 10 mGy, 15 mGy, 30 mGy and 500 mGy using an X-RAD 225 cabinet 
(Precision X-ray Inc, North Branford, United States of America).  Samples were placed in an 
incubator at 37ºC for 30 minutes prior to undergoing the γH2AX protocol, allowing time for 
DNA damage signaling[27]. 
 
Lifetime attributable risk cancer mortality estimation    
In addition to calculating effective dose, PCXMC also provided the LAR of cancer mortality 
for each participant using effective dose using Biological Effects of Ionising radiation (BEIR) 
risk models[33].  Each child’s age and ethnicity was inputted into the PCXMC program.  LAR 
of cancer mortality was also estimated using a second method which involved  γH2AX-foci 
observations.  In order to perform this estimation the mean number of γH2AX-foci induced by 
the in vitro irradiation for 500 mGy was determined (mean = 5.25 foci per cell).  A dose of 500 
mGy was chosen because cancer mortality risk data is available for 500 mGy in the BEIR 
report (Biological Effects of Ionising radiation, 2006) [33].   The risk factor at 500mGy  was 
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then scaled and used with the in vitro dose response curve performed using blood doses of 0-
30 mGy to estimate the cancer mortality risk. The calculations were performed as follows; 
cancer risk for 500 mGy (from BEIR report [33]  ) divided by in vitro mean foci observation for 
500 mGy (5.25) and multiplied by each participant foci observation to calculate their individual 
risk. For example we would estimate the LAR of cancer mortality for a 14 year old male patient 
with a mean number of induced γH2AX-foci of 0.046 and a LAR of 3% for 500 mGy (BEIR) 
as follows. We divided his cancer risk of 3% by the in vitro mean foci observation for 500 mGy 
(5.25) and multiplied this by the foci observation from his blood sample (0.046). i.e. 
3/5.25x0.046 = 0.03%   Therefore his LAR of cancer mortality was calculated as 0.03%.   
 
Statistical analysis 
Statistical Package for Social Science 22 (SPSS Inc, Chicago, IL, USA) was used to assess the 
relevant data.   Pre paediatric cardiac catheterisation procedure baseline samples between 
participants were evaluated using a one-way ANOVA with Tukey post hoc tests.  Differences 
in radiation dose, image quality scores, mean γH2AX-foci and LAR of cancer mortality for 
each imaging method were analysed using descriptive statistics.  Differences between pre and 
post radiation γH2AX-foci observations were evaluated using the paired sample Wilcoxon 
signed-rank test.  A Spearman’s correlation coefficient was used to evaluate the relationship 
between γH2AX-foci and radiation dose, and LAR of cancer mortality and cancer mortality 
estimates using γH2AX-foci observations.  Kappa measure of agreement was used to determine 
the inter-observer agreement between clinical image scorers.  A Grubbs test was used to 
evaluate radiation dose and identify statistical outliers.  
 
 
Results 
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Procedures 
A total of 22 diagnostic and 48 interventional procedures were performed.  On average 
participant size was similar for each imaging method (Table 1).  One outlier was identified and 
removed from analysis during the study period.  This participant received a dose area product 
of 6,672.4 cGycm², more than double the second largest dose area product, and had undergone 
an unusually complex and difficult procedure.  A summary of the imaging parameters and 
procedure types are demonstrated in Table 2.  Information on each participant size, weight and 
DAP values has been provided in Table 3. The tube potential used throughout the study ranged 
between 62 - 102 kVp.  The anti-scatter grid group had the lowest mean fluoroscopy time 
(663±556) and the lowest total number of total CINE acquisitions (146).  Compared to the anti-
scatter grid group, mean tube current was 40% less for the no anti-scatter grid group and 25% 
less for the 15 cm anti-scatter group. The majority of examinations were interventional and 
mostly treated patent ductus arteriosus and atrial septal defects.  The majority of X-ray beam 
angulations for fluoroscopy were performed in the posterior-anterior and lateral views.   
 
Image quality  
Image quality was deemed acceptable throughout all procedures and were completed without 
a request by the operating clinician to reinsert the anti-scatter grid.  A sample image comparison 
of lateral CINE projections performed on participants weighting 10 - 20 kg for each image 
method is demonstrated in Figure 2.  Kappa measure of agreement demonstrated significant 
correlation between the blinded image scorers (p <0.05).  Image quality was regarded as 
sufficient when the image score was ≥0.  The mode score for image quality characteristics was 
2 (Fully confident that criterion is fulfilled) for each imaging method.  All 3 imaging methods 
scored a 0 for image sharpness in participants >10 kg for the visualisation of 
balloons/stents/devices on at least 1 occasion. The mode score for overall image quality was 1 
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(good image quality, no limitations for clinical use) for each imaging method.  Only 1 negative 
score was given throughout the scoring.  This was a score of -1 (somewhat confident criterion 
is not fulfilled), specifying difficulty visualising a pulmonary stent in a participant weighting 
52 kg using the no AS grid method during fluoroscopy in a left anterior oblique 65º, cranial 
35º angulation. 
 
Dosimetry  
A summary of the radiation dose recorded for each imaging method is provided in Table 4.  
Compared to the anti-scatter grid group (843±870), the mean dose area product was 53% lower 
for the no anti-scatter grid group (396±152) and 20% lower for the 15 cm air-gap group 
(678±773).  Similarly, the same trend was observed for effective dose, peak skin dose and 
organ doses.  All peak skin dose estimations were considerably lower than the deterministic 
skin injury threshold of 2 Gy.  The largest peak skin dose was observed in the outlier participant 
(481 mGy), whilst the second largest was observed in a participant imaged using the anti-scatter 
grid method (275.6 mGy). 
 
Assessment of DNA double-strand breakages   
One participant did not consent for a blood sample to be taken therefore the γH2AX assay was 
performed on 69 of the 70 participants.  No significant difference was found between numbers 
of γH2AX-foci in the pre samples (p >0.05).  An increase in γH2AX-foci was observed in each 
participant who underwent paediatric cardiac catheterisation.  Pre radiation mean γH2AX-foci 
values ranged from 0 - 0.07 (up to 22/300 double-strand breakages) whilst mean post radiation 
γH2AX-foci ranged from 0.006 - 0.41 (up to 118 radiation-induced double-strand breakages 
from 300 cells).  The mean numbers of radiation-induced γH2AX-foci for each imaging 
method are demonstrated in Figure 3.  The Wilcoxin signed-rank test showed a significant 
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increase in γH2AX-foci following paediatric cardiac catheterisation for 84% of participants (p 
<0.05).  The lowest radiation dose that led to a significant increase in γH2AX-foci (0.02) was 
observed in a 1-year-old who received a dose area product of 81 cGycm² using the anti-scatter 
grid for a diagnostic procedure.  The largest mean increase in γH2AX-foci (0.35) was observed 
in an 8-year-old who received a dose area product of 2,617.4 cGycm² using the anti-scatter grid 
method for a diagnostic assessment of previous intervention for tetralogy of fallot.   Compared 
to the mean number of radiation-induced γH2AX-foci using the anti-scatter grid method 
(0.1±0.08) mean γH2AX-foci were 30% and 20% lower for the no anti-scatter grid (0.07±0.06) 
and 15 cm air-gap (0.08±0.07) methods respectively.  Almost all participants imaged with the 
anti-scatter grid (96%) had significant increases in mean γH2AX-foci beyond their background 
(pre) level, whilst for the no anti-scatter grid (77%) and 15 cm air-gap (83%) this figure was 
lower.   
 
Lifetime attributable risk of cancer mortality  
The in vitro dose response curve performed using lower blood doses of 0-30 mGy and the 
number of radiation-induced γH2AX-foci for each participant (Figure 4) was used to estimate 
a cancer mortality risk for each participant. The LAR of cancer mortality for participants is 
demonstrated in Table 5.  Estimates using the biological effects of ionising radiation ranged 
from 0.03 - 4.8 per 1,000 (mean 0.09 per 1,000).  When compared to the anti-scatter grid 
method, LAR of cancer mortality was 18 - 45% lower for the no anti-scatter grid method and 
12 - 45% lower for the 15 cm air-gap method.  Pearsons correlation coefficient demonstrated 
a significant agreement between biological effects of ionising radiation estimates and γH2AX-
foci risk estimates (p <0.05).  These observations showed that γH2AX-foci, as a measure of 
DNA double-strand breakages, when compared with the PCXMC BEIR estimates 
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demonstrated an agreement with the linear no-threshold model of radiation-induced cancer risk 
estimates for < 500 mGy. 
 
Discussion  
This is the first study to use biomarker evidence following implementation of dose optimisation 
in paediatric cardiac catheterisation.  The data presented is the largest known study to assess 
double-strand breakages as a result of ionising radiation exposure to children, and from 
paediatric cardiac catheterisation procedures. Children that received a dose area product as low 
as 81 cGycm² resulted in significant amounts of double strand breakages; the most significant 
DNA lesions induced by ionising radiation.  Although these double-strand breakages were 
undergoing repair, there is an increased risk of a non-repair or misrepair event, potentially 
leading to carcinogenesis[34].  Our baseline levels of double-strand breakages were within the 
region expected for non-irradiated blood lymphocyte cells (<0.1)[35-36].  We used our ex vivo 
double-strand breakage observations to interpret the in vivo findings.  Although our in vivo 
correlation between foci and blood dose was weaker than ex vivo, likely because of repair 
already occurring during paediatric cardiac catheterisation, an increase in double-strand 
breakages clearly occurred with increasing radiation dose to participants.  The no anti-scatter 
grid method and the consequent reduction in radiation dose, resulted in an average reduction 
in DNA damage of 30%, whilst for the 15 cm air-gap, the average reduction was 20%.  The 
observed amounts of DNA damage repair are in general agreement with previous in vivo 
investigations in children undergoing medical imaging[26-28]. Almost all participants imaged 
with the anti-scatter grid (96%) had significant increases in mean γH2AX-foci beyond their 
background (pre) level, whilst for the no anti-scatter grid (77%) and 15 cm air-gap (83%) this 
figure was lower.  This would indicate that 23% and 17% of participants undergoing the 
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proposed optimisation techniques maintained DNA integrity at pre intervention levels at these 
radiation doses.  
 
 
The estimated LAR of cancer mortality used biological effects of ionising radiation risk models 
took into consideration the age and gender of the participants.  The linear no-threshold model 
assumes that there is no safe amount of ionising radiation and therefore all exposures no matter 
how low, carry some risk.  The range of percentage LAR of cancer mortality reported in males 
(0.02 - 0.53) and females (0.011 - 0.53) from previous investigation[26] resemble the range of 
estimates found in our study using the anti-scatter grid method for males (0.017 - 0.48) and 
females (0.03 - 0.4).  In comparison these were lower for the no anti-scatter grid method (males: 
0.003 - 0.18, females: 0.03 - 0.24) and 15 cm air-gap method (males: 0.01 - 0.18, females: 
0.004 - 0.18).  We found LAR cancer mortality estimates using γH2AX-foci observations were 
similar to the PCXMC  BEIR estimates and therefore support the current consensus of the 
linear no-threshold model.  This finding is contrary to a previous investigation, which used 
γH2AX-foci observations, finding that LAR of cancer mortality using γH2AX-foci data was 
four times greater (4 per 1000) than biological effects of ionising radiation estimates (1 per 
1000)[28]. 
 
The results of our random clinical implementation of scatter removal techniques suggest that 
removal of the anti-scatter grid in routine diagnostic and interventional paediatric cardiac 
catheterisation is feasible.  The average dose reductions observed by reverting to a no anti-
scatter grid method (53%) or 15 cm air-gap method (20%) also demonstrated sufficient image 
quality for successful completion of all paediatric cardiac catheterisation procedures in 
participants up to 15 years of age, 99 kg and 22 cm chest diameter.  These dose reductions are 
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likely because the tube current for the anti-scatter grid was 40% and 25% greater than the no 
anti-scatter grid and 15 cm air-gap methods.  This was expected because the X-ray system uses 
an automated exposure control to maintain a constant detector dose, therefore tube current is 
automatically increased using an anti-scatter grid.  This occurs because useful X-ray photons 
are absorbed by the interspaced material positioned within the lead strips of the anti-scatter 
grid. It is important to note that these reductions in dose were observed in spite of an increase 
in fluoroscopy time and the number of acquisitions undertaken in both the group where the 
anti-scatter grid was removed and the group with the air gap. This implies that dose reduction 
was achieved by employing these techniques irrespective of the complexity of the case but may 
also indicate extra procedural time required to complete the examination due to reduced image 
quality.  
 
Mean effective dose observations ranged from 4.55 mSv (no anti-scatter grid) to 6.78 mSv 
(anti-scatter grid).  These observations are comparable with the range observed in previous 
dosimetry studies for paediatric cardiac catheterisation[4,37-39].  The greatest internal organ 
radiation doses occurred to the heart and lungs and on average were lower when the anti-scatter 
grid was removed.  Regardless of the imaging method, observed organ doses were substantially 
below the 500 mGy dose, whereby evidence of radiation-induced cardiovascular disease 
exists[40].  Although only approximated, peak skin dose observations were considerably lower 
than the deterministic threshold of 2 Gy.  These findings are consistent with previous findings 
that patients <18 years of age have considerably lower risk of skin injury compared to adults[41].   
However it should be acknowledged that the average age in our study was five years.  It could 
be useful further assess peak skin dose because published dosimetry observations have shown 
a marked increase in radiation doses for children >10 years[4,34].       
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Our findings are comparable with previous phantom experiments[10,13], whereby image quality 
was deemed sufficient for small children (<10 kg).  The results also support the suggestion[12] 
that the anti-scatter grid may be removed for larger patients (>10 kg).  Supplementary image 
quality scoring helped operating clinicians reflect upon a random sample of images used for 
each imaging method.  Interestingly, all three imaging methods showed moderate lack of image 
sharpness for the visualisation of balloons/stents/devices on at least one occasion.  This 
indicates that image quality could be comparable and that perhaps temporarily increasing the 
detector dose could remedy this problem.  Our X-ray system enables the selection “fluoro 
flavours” that may boost image quality (at the expense of increasing the radiation dose) for a 
brief period.  The negative score for the visualisation of a pulmonary stent in a large participant 
using the no anti-scatter grid method during fluoroscopy with a steep imaging angle, has 
identified potential scenario justifying the use of the anti-scatter grid. 
 
 
The use of automatic exposure control flat panel detector imaging systems without an anti-
scatter grid in situ substantially lowers radiation dose to the patient.  Less scatter radiation 
occurs when imaging smaller patients and a lower tube output by removing the anti-scatter grid 
will also inevitably result in less scatter radiation.  Our study has shown, that during paediatric 
cardiac catheterisation, the amounts of scatter radiation in newborns and small children up to 
approximately 20 kg may be insufficient to degrade the task dependant image quality in a range 
of typical paediatric cardiac catheterisation procedures.  This may also be applicable to larger 
children but requires further evaluation.  The use of the 15 cm air-gap was also used as a dose 
optimised method and could be useful for larger children.  
 
Limitations  
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Recruited during the 1-year period was restricted to 1 - 3 per week because the departmental 
workload consisted mostly of adult patients.  Only one imaging centre was used in the data 
collection whilst operating clinicians in other centres may have a different opinion on the task 
dependant image quality.  Other imaging centres may have different X-ray beam angulation 
preferences and this may affect image quality differently.  The radiation dose measurements 
calculated in our study are best estimates only.  The fundamental measurement of radiation 
exposure was the dose area product, which as a measurement, does not reflect the amount of 
radiation absorbed by each participant.  Monte Carlo software conversion factors were used to 
provide effective dose estimates however these methods provide crude estimates and have 
inherent inaccuracies of up to 40% [31]. There was also potential inaccuracy calculating 
effective and organ doses because assigning patients to the closest phantom age can result in 
errors as large as 25%[42].  It is important to emphasise that the observed double-strand 
breakages were undergoing repair and that we did not determine if full repair of double-strand 
breakages occurred.  It is possible DNA damage observations did not capture all double-strand 
breakages because paediatric cardiac catheterisation is a lengthy procedure and the optimal 
time of capture for double-strand breakages is 30 minutes post irradiation[43].  The DNA 
damage observed was limited to blood lymphocytes and therefore the biological effects has not 
assessed the amount of DNA damage in regions such as the bone marrow, lung and breasts.  It 
is also not possible to determine how many lymphocytes within the sample obtained were 
directly exposed to radiation during the procedure.  
 
Future consideration 
There are no official guidelines for best clinical practice in paediatric cardiac catheterisation.  
Our findings require further validation on a larger cohort due to the wide variation in patient 
size, types of congenital heart disease, imaging angulations and procedural complexity 
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associated with paediatric cardiac catheterisation.  Consideration could be given to adapting 
other components such as “fluoro flavours” temporarily during the procedure rather than use 
of the anti-scatter grid.  Innovation of remote control instantaneous anti-scatter grid placement 
and removal could also be employed in similar fashion.  Investigations using the γH2AX assay 
have demonstrated significant reductions in radiation-induced double-strand breakages in 
blood lymphocytes irradiated in vitro with 10 mGy following oral ingestion of antioxidants[44-
45].  Therefore the potential protective measure of antioxidant supplementation should be 
further investigated in paediatric cardiac catheterisation.  Obtaining blood samples post 24 
hours from paediatric cardiac catheterisation may also help identify persistent double-strand 
breakages.  
 
Conclusion 
This is the first study to employ the γH2AX assay a biomarker of radiation dose reduction 
during alterations to cardiac catheterisation procedures. Radiation doses received during 
paediatric cardiac catheterisation procedures resulted in a significant increase in DNA damage. 
Our study suggests it is feasible to implement removal of the anti-scatter grid in paediatric 
cardiac catheterisation to optimise the radiation dose and maintain DNA integrity. Interestingly 
DNA integrity was maintained in 23% and 17% of cases which  may be due to ongoing DNA 
repair. However, caution should be given to larger children for employing 
balloon/stent/devices, whereby the use of a 15 cm air-gap may be preferable.  Our findings 
showed acceptable image quality and substantial reductions in radiation dose.  Consequently, 
a substantial reduction in DNA damage and cancer mortality risk has been presented.  Based 
upon our work, a larger investigation is warranted and we hope that presented material will 
further the knowledge for clinicians making risk-benefit decisions during imaging for 
paediatric cardiac catheterisation. 
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Figure	1	equipment	with	grid	in	situ	(a)	and	following	removal	of	the	grid	by	
depressing	the	safety	catch	(b).			
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Figure	2.	Lateral	CINE	image	frames	for	assessment	of	patent	ductus	arteriosus	in	
10	‐	20	kg	participants	for	each	imaging	method	
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Figure 3.  Mean and standard deviation of pre and post γH2AX-foci observations for 
each imaging method 
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Figure 4. Mean and standard error for in vivo γH2AX-foci observations for all 69 
participants and in vitro observation in a health volunteer. 
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Table 1.  Summary of participant characteristics 
 
 
 
 Anti-scatter grid No anti-scatter grid 15 cm air-gap 
Patients (n) 24 23 23 
Males (n) 12 13 12 
Females (n) 12 13 11 
*Age (months) 70.7±58.2 63.3±42.3 77.2±53.4 
*Weight (kg) 23±16 20.1±12 24.8±21.1 
*Chest diameter (cm) 12.9±2.8 12.4±1.8 12.7±3.1 
 
 
* data presented as mean and +/- standard deviation 
Chest diameter measured using callipers 
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Table 2.  Summary of X-ray parameters and examination types. 
 
 
 
 
 Anti-scatter grid No anti-scatter grid 15 cm air-gap 
*Fluoroscopy time (s) 663±556 813±633 843±573 
*Tube potential (kVp) 71±3.4 68±4.2 67±4 
*Tube current (mA) 357±214 216±93 267±163 
*CINE time (s) 4.3±1.4 4.3±1.3 4.1±2.1 
Total CINE acquisitions (n) 146 177 151 
Diagnostic (n) 5 8 9 
Patent ductus arteriosus  (n) 10 9 5 
Atrial septal defect (n) 3 1 6 
Pulmonary valve stenosis (n) 2 1 0 
Aortic valve stenosis (n) 1 1 1 
Aortic stenosis  1 0 0 
Pulmonary artery stenosis (n) 2 1 1 
Permanent pacemaker (n) 0 1 1 
 
 
 
* Data presented as mean and +/- standard deviation  
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Table 3. Patient size, weight and DAP values.  
Imaging method Age 
(months) 
Weight 
(kg) 
Height 
(cm) 
Chest 
thickness (cm) 
DAP 
(cGycm²) 
Anti-scatter grid 96 27.2 129.3 13.5 2617.4 
Anti-scatter grid 16 7.86 70 10.5 266.3 
Anti-scatter grid 61 14 101.5 13 545.1 
Anti-scatter grid 2 4.95 57.5 9 121.3 
Anti-scatter grid 105 34 147 11 463.4 
Anti-scatter grid 101 31 129 14 1079.4 
Anti-scatter grid 19 11.15 80.5 12 81.4 
Anti-scatter grid 17 12 85.5 9 199.8 
Anti-scatter grid 19 10.76 86 10.5 162.7 
Anti-scatter grid 34 13.42 88.8 11 212.8 
Anti-scatter grid 6 7.8 70 11 140.8 
Anti-scatter grid 0 3.3 51 8.5 34 
Anti-scatter grid 40 13.4 95 12.5 2836.9 
Anti-scatter grid 99 30 126 15 1092.9 
Anti-scatter grid 23 10.6 75 12 213.1 
Anti-scatter grid 72 22.5 121.1 15 349.9 
Anti-scatter grid 171 40 159 16.5 880 
Anti-scatter grid 162 51 165 17 2529.8 
Anti-scatter grid 138 53 159.5 19 585 
Anti-scatter grid 43 16.1 94.5 12.5 266.8 
Anti-scatter grid 173 44 158.5 17 1447.6 
Anti-scatter grid 178 59 162 17 958.2 
Anti-scatter grid 46 15 102 12 814.2 
Anti-scatter grid 78 22 117 13 2330 
No anti-scatter grid 29 11.5 87 11.00 211.8 
No anti-scatter grid 156 46 157 15.50 308.7 
No anti-scatter grid 106 38.7 146.3 14.00 4.34 
No anti-scatter grid 8 6.2 67 8.50 115.7 
No anti-scatter grid 133 32 139.6 15.50 648.9 
No anti-scatter grid 60 17.5 109 13.00 342 
No anti-scatter grid 138 52 147.5 16.00 6672.4 
No anti-scatter grid 84 16.54 107.5 11.50 481.1 
No anti-scatter grid 49 18.62 108.1 11.2 157.6 
No anti-scatter grid 63 18 102 10.2 764.3 
No anti-scatter grid 16 9.25 85 11 101.2 
No anti-scatter grid 11 9 75 11 129.8 
No anti-scatter grid 73 17 109.5 12.5 196.6 
No anti-scatter grid 96 26 124.4 14 970.5 
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No anti-scatter grid 62 16.5 107.5 12 164.7 
No anti-scatter grid 32 13.5 97 11.5 380.9 
No anti-scatter grid 39 14.95 93 12.5 266.5 
No anti-scatter grid 51 17.65 11 14 925.8 
No anti-scatter grid 58 14.5 106 12.8 1418.4 
No anti-scatter grid 6 6 67 11 315.4 
No anti-scatter grid 20 11.5 86.5 11 92 
No anti-scatter grid 63 24.85 114 13 504 
No anti-scatter grid 104 26 115 12 216.9 
15 cm air-gap 168 57 172 17 998.6 
15 cm air-gap 39 14.55 92.5 12 1240.2 
15 cm air-gap 56 18.4 108 11.5 790.4 
15 cm air-gap 100 24 130 13.5 262.7 
15 cm air-gap 51 17.1 100.5 11.5 825.8 
15 cm air-gap 48 16 101 12 338.7 
15 cm air-gap 90 21 119.5 11 697 
15 cm air-gap 140 25 121.5 12.5 27.8 
15 cm air-gap 68 23.5 110 13 374.1 
15 cm air-gap 8 8.05 70 9 393.4 
15 cm air-gap 183 99 170 18.5 2755.4 
15 cm air-gap 51 14 94 11 154.4 
15 cm air-gap 36 12.38 85 11.5 367.9 
15 cm air-gap 24 11.2 82 10.5 134.8 
15 cm air-gap 75 16.85 90 13.5 226 
15 cm air-gap 6 7.3 68 10 162.2 
15 cm air-gap 42 11.3 98 8 88.6 
15 cm air-gap 54 16.35 102 13 886 
15 cm air-gap 22 10.5 80 10 330.3 
15 cm air-gap 107 32 143 17 171 
15 cm air-gap 87 22.2 108 12 221.7 
15 cm air-gap 132 32.5 148 13 1191.3 
15 cm air-gap 190 61 164 22 2946.5 
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Table 4.  Summary of mean and standard deviation of radiation dose estimations using 
each imaging method 
 
 
Organ 
 
Anti-scatter grid 
 
No anti-scatter grid 
 
15 cm air-gap 
 
DAP (cGycm²) 
 
843±870 
 
396±352 
 
678±774 
 
Effective dose (mSv) 
 
6.78±7.72 
 
4.45±3.73 
 
4.66±3.39 
 
Peak skin dose (mGy) 
 
52.2±57.9 
 
21.5±16.5 
 
45.6±46.2 
 
Lung (mGy) 
 
23.9±22.7 
 
15.1±12.5 
 
17.5±12.2 
 
Heart (mGy) 
 
18.3±18.6 
 
10.6-7.7 
 
12.1±7.5 
 
Oesophagus (mGy) 
 
16.6±18.9 
 
9.1±6.5 
 
11.3±8.3 
 
Adrenal (mGy) 
 
17.9±46.2 
 
5.2±6.2 
 
6.5±5.4 
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Table 5.  Mean and standard deviation of percentage LAR of cancer mortality for males 
and females for each imaging method using BEIR estimates and calibrated γH2AX-foci 
observations. 
 
 
 
 
 
 Anti-scatter grid No anti-scatter grid 15 cm air-gap 
 
 
 
Males 
 
BEIR 
 
0.09±0.04 
 
0.05±0.05 
 
0.07±0.04 
 
 
FOCI 
 
0.09±0.06 
 
0.06±0.04 
 
0.08±0.07 
 
 
 
Females 
 
BEIR 
 
0.11±0.1 
 
0.09±0.06 
 
0.09±0.06 
 
 
FOCI 
 
0.11±0.1 
 
0.08±0.09 
 
0.06±0.04 
 
 
 
 
 
 
 
 
 
 
	
	
